All lobbying filings

THE MCMANUS GROUP

Lobbying for INFUSION PROVIDERS ALLIANCE · Association representing infusion drug providers.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Delaware · House · Senate · $90,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 1

HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act

Lobbying activity 2

Health Issues

Advocating for access to and reimbursement for biosimilars.

Medicare/Medicaid

Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.